EGFR antibodies in resectable metastatic colorectal liver metastasis: more harm than benefit?

Gholami, Sepideh, Grothey, Axel (March 2020) EGFR antibodies in resectable metastatic colorectal liver metastasis: more harm than benefit? The Lancet Oncology, 21 (3). pp. 324-326. ISSN 1470-2045

[thumbnail of 2020_Gholami_EGFR_antibodies_in_respectable.pdf]

Preview

PDF
2020_Gholami_EGFR_antibodies_in_respectable.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.
Download (217kB) | Preview

URL: https://www.ncbi.nlm.nih.gov/pubmed/32014120

DOI: 10.1016/S1470-2045(20)30003-6

Item Type:	Paper
Subjects:	diseases & disorders diseases & disorders > neoplasms diseases & disorders > cancer > cancer types > colon cancer diseases & disorders > cancer > cancer types > colon cancer bioinformatics > genomics and proteomics > genetics & nucleic acid processing > protein structure, function, modification > protein types > EGFR diseases & disorders > cancer > metastasis
CSHL Authors:	Gholami, Sepideh
Communities:	CSHL labs > Gholami Lab
SWORD Depositor:	CSHL Elements
Depositing User:	CSHL Elements
Date:	March 2020
Date Deposited:	05 Oct 2023 18:09
Last Modified:	29 Jan 2024 21:21
Related URLs:	Publisher
URI:	https://repository.cshl.edu/id/eprint/41137

Actions (login required)

Administrator's edit/view item